# Prevention of Thromboembolic Events in Total Knee Replacement Patients

> **NCT03393481** · PHASE2 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Thrombotic Disorders

## Interventions

- **DRUG:** MAA868
- **DRUG:** Enoxaparin

## Key facts

- **NCT ID:** NCT03393481
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-10-03
- **Primary completion:** 2020-01-08
- **Final completion:** 2020-04-17
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Trial cancelled before First Patient First Visit (no patient enrolled)
- **Last updated:** 2020-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03393481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03393481, "Prevention of Thromboembolic Events in Total Knee Replacement Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03393481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*